2.99
0.05 (1.7%)
0.05 (1.7%)
Upgrade to Real-Time
Afterhours (Closed)
| Volume | 141,037 |
|
|||||
| News | - | ||||||
| Day High | 3.00 | Low High |
|||||
| Day Low | 2.86 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| ESSA Pharma Inc | EPIX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.05 | 1.7% | 2.99 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 2.91 | 2.86 | 3.00 | 2.95 | 2.94 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,039 | 141,037 | $ 2.92 | $ 411,367 | - | 1.40 - 10.985 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 18:27:59 | formt | 1,000 | $ 2.99 | USD |
Period:
Draw Mode:
ESSA Pharma Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 86.74M | 29.01M | 26.54M | $ - | $ - | -0.81 | -3.40 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 2.66M | 2.50% |
ESSA Pharma News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EPIX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.67 | 3.00 | 2.65 | 2.84 | 218,775 | 0.32 | 11.99% |
| 1 Month | 2.62 | 3.00 | 2.50 | 2.76 | 368,267 | 0.37 | 14.12% |
| 3 Months | 3.30 | 4.15 | 2.29 | 3.03 | 319,502 | -0.31 | -9.39% |
| 6 Months | 2.97 | 5.16 | 1.40 | 4.33 | 1,748,234 | 0.02 | 0.67% |
| 1 Year | 9.03 | 10.985 | 1.40 | 4.39 | 1,056,418 | -6.04 | -66.89% |
| 3 Years | 5.55 | 36.00 | 1.40 | 7.87 | 501,809 | -2.56 | -46.13% |
| 5 Years | 0.2129 | 36.00 | 0.10 | 7.65 | 316,083 | 2.78 | 1,304.42% |
ESSA Pharma Description
| ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. |